Revolutionizing high-throughput screening for faster biologic drug discovery

Beckman Coulter Life Sciences, a Danaher Corporation company, has introduced the Cydem VT Automated Clone Screening System, a groundbreaking platform designed to expedite cell line development for biologic drug discovery and monoclonal antibody (mAb) therapeutics.

This high-throughput microbioreactor platform minimizes manual steps in clone screening by up to 90%, reducing timelines and optimizing productivity. Designed for cultivating Chinese Hamster Ovary (CHO) cell lines, the system closely mirrors biomanufacturing conditions to deliver early and reliable insights into cell growth and productivity.

Key features of the Cydem VT system:

• High-Throughput Parallel Cultivation: Up to 96 pH-controlled, fed-batch bioreactors with individual gassing.
• Automated Workflows: Offers three days of walk-away time with continuous cultivation monitoring.
• Integrated Measurements: Includes online pH, dissolved oxygen (DO), and biomass monitoring.
• Comprehensive Screening Tools: On-deck cell concentration, viability, and titer analysis for precise clone selection.
• Enhanced Efficiency: Cuts out unnecessary traditional screening steps while ensuring superior results.

This all-in-one platform empowers researchers to confidently identify the top clones, bringing life-saving therapies to market faster.